Cholesterol (CS) exerts essential physiological functions as a constituent of biological membranes and precursor of steroid hormones and bile acids (BAs). CS balance is the result of an equilibrium between dietary and biliary CS absorption, cellular de novo synthesis, and hepatic catabolism into BAs. A dysregulation of these input and output pathways produces metabolic disorders leading to gallstones formation and the development of atherosclerosis.
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Cholesterol (CS) exerts essential physiological functions as a constituent of biological membranes and precursor of steroid hormones and bile acids (BAs). CS balance is the result of an equilibrium between dietary and biliary CS absorption, cellular de novo synthesis, and hepatic catabolism into BAs. A dysregulation of these input and output pathways produces metabolic disorders leading to gallstones formation and the development of atherosclerosis.
Molecular mechanisms contributing to CS homeostasis are progressively elucidated. They are supported by a set of transcriptional factors directly activated by both CS and its metabolic derivatives, BA and oxysterols. CS modulates the transcription rate of target genes through the action of specific transcriptional factors termed sterol regulatory element-binding proteins (SREBPs) (1) . In contrast to the other members of the basic helix-loop-helix zipper family, SREBPs are synthesized as inactive precursors bound to endoplasmic reticulum membrane and nucleus envelope. In cultured cells, CS depletion triggers the proteolytic release of an active NH2-terminal domain which, after translocation into the nucleus, induces the transcription rate of sterol target genes. Conversely, the proteolytic activation of SREBPs and the transcriptional activity of target genes are low, when the cellular CS levels are increased (1, 2) . BAs and oxysterols, also affect the CS balance through regulatory pathways recently depicted which involve different nuclear hormone receptors. BAs are the natural agonists of the Farnesoid-X-Receptor (FXR) (NR1H4) (3, 4) , while oxysterols specifically activate the Liver-X-Receptor α and β (LXRs) (NR1H3 and NR1H2) (5) . Once activated, these nuclear receptors bind, as heterodimers with 9-cis retinoic acid receptor (RXR), specific responsive elements located in the promoter of target genes (6, 7) .
BA synthesis and elimination are major determinants for body CS homeostasis. Primary BAs are synthesized from CS in the liver where they are conjugated with glycine or taurine prior to be secreted into bile. More than 90% BAs are reabsorbed along the small intestine and return to the liver to be secreted again into bile. This enterohepatic BAs circulation is essential for 5 absorption is supported by the fact that patients with a mutation in the I-BAT gene or with a diminished expression level of I-BAT, as in familial hypertriglyceridemia, fail to absorb BAs efficiently (9, 10) . Once into the cell, BAs are reversibly bound to I-BABP, also termed ileal lipid-binding protein (ILBP). It is an abundant soluble 14 kDa protein which belongs to the fatty acid-binding protein superfamily (11) . As the other members of this multigenic family, the tertiary structure of I-BABP consists of 10 antiparallel β strands organized into 2 orthogonal β sheets forming an hydrophobic pocket (12). Specificities in the I-BABP structure (high volume cavity, great flexibility of the backbone structure) account for its preferential binding of bulky hydrophobic and rigid ligands such as unconjugated and conjugated BAs (13). In the digestive tract, I-BABP is found in both small intestine and liver in which its expression is strictly restricted to the ileocytes (14,15) and large cholangiocytes 
MATERIALS AND METHODS
Animals and experimental treatments-French guidelines for the use and care of laboratory animals were followed. Male Swiss mice (30 ± 2 g) from the Centre d'Elevage Dépré (France) were used. Animals were housed individually in a controlled environment (constant temperature and humidity, darkness from 8 p.m. to 8 a.m.) and fed ad libitum a standard chow (UAR A04, Usine d'Alimentation Rationnelle, France). To explore the effects of a high CS diet on I-BABP gene expression, mice were fed for 14 days a standard chow supplemented with 2% CS (w/w). Controls were fed the standard chow containing <0.02% CS. In second set of experiments, mice were either sacrified 24 h after a gavage with a specific LXR agonist (36 mpk GW3965). Controls received by force feeding the vehicle alone (0.9% carboxy methyl cellulose, 9% polyethylene glycol 400 and 0.05% Tween 80). After sacrifice, the ileal mucosa corresponding to the 5 cm intestinal segment before the cecum were scraped, snap frozen in liquid nitrogen, then stored at -80 °C until RNAs extraction.
Cell culture-Caco-2 cells (passages 55-60) were cultured in controlled environment (37°C, 5% CO 2 ) in medium A (Dulbecco's Modified Eagle Medium (DMEM), 4 mM glutamine, 1% non-essential amino acids, 100 units/ml penicillin, 100 µg/ml streptomycin) supplemented with 20% fetal calf serum (FCS). Medium was changed every 2 days. At the first day of confluency, cells were incubated for 24 hours in the medium A containing 10% fetal calf serum (v/v) in presence of 50 µM chenodeoxycholic acid (CDCA) alone (Control), or associated with either 5 µg/ml simvastatin (Sterols -), or 10 µg/ml CS and 1 µg/ml 25- 
RESULTS

Sterols Regulate I-BABP mRNA Levels In Vitro-In undifferentiated Caco-2 cells cultured
under standard conditions, I-BABP mRNA levels are too low to detect a putative inhibitory effect. Since chenodeoxycholic acid (CDCA) is known to be a strong I-BABP gene inducer (19), the effect of a sterol addition (10 µg/ml CS + 1 µg/ml 25(OH)CS) or depletion (5 µg/ml HMG-CoA reductase inhibitor, simvastatin) on I-BABP mRNA levels was studied on cells simultaneously subjected to 50 µM CDCA. According to previously published data (19),
CDCA alone led to a 2-fold increase in I-BABP transcripts as compared to the control culture (data not shown). As shown in the Fig. 1 , the I-BABP mRNA levels were significantly increased when Caco-2 were sterol-deprived, and repressed when the sterols were added to the medium. Similar modifications in mRNA levels have also been found for the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA ) reductase which is known to be a typical sterol target gene (data not shown). ) flanking the SRE conserved in these different mammalian species (Fig. 3) . Deletion/mutation analyses of the short promoter confirmed the importance of these sequences (Fig. 4) . Indeed, the strong induction of the CAT activity triggered by sterol depletion in the wild type promoter (148 I- days a standard chow supplemented with 2% CS. Surprisingly, the I-BABP mRNA levels were significantly higher in the ileum from mice subjected to the CS supplementation than in animal fed the control diet (Fig. 6-A) . Interestingly, ileal SREBP1c mRNA levels were also significantly increased by the high CS diet, whereas the transcripts encoding SREBP1a were unchanged ( Fig. 6-B) , and as previously reported, SREBP2 mRNA levels were reduced by the CS feeding (30,31). To determine whether the SREBP1c isoform can specifically bind to the SRE I-BABP motif, electrophoretic mobility shift assays (EMSA) were performed using the conditions, GW3965 led to a slight but significant increase in both I-BABP and SREBP1c
Identification of a SRE in the Human I-BABP Promoter-
( Fig. 8-B) . 14 In contrast to these in vitro data, a CS-enriched diet led to a significant rise in I-BABP mRNA levels in the mouse ileum ( Fig. 6-A showing that SREBP1c is a direct LXR target gene in contrast to other SREBP isoforms (31,43). In mice, CS feeding, which is a source of oxysterols ligands for LXR (5), leads to the hepatic up-regulation of SREBP1c gene through an LXRE located in its proximal promoter (31). In the present data, a similar CS supplementation (i.e. 2% CS for 14 days) also produces the rise of SREBP1c mRNA levels in the mouse ileum ( Fig. 6-B) . Since SREBP1c and I-BABP are co-located in mature ileocytes (41,44), it is likely that the CS-mediated I-BABP increase reported here is, at least in part, the result of the induction of SREBP1c gene expression. Since, LXR agonist GW3965 treatment leads both in vivo and in vitro to an increase in I-BABP and SREBP1c transcripts in the mouse ileum (Fig. 8) 
